SECsense Logo

Mangoceuticals, Inc. 8-K Report: Key Insights & Recent Developments

$MGRX
Form 8-K
Filed on: 2024-12-26
Source
Mangoceuticals, Inc. 8-K Report: Key Insights & Recent Developments

Based on the provided XML section of the financial report, here are the key pieces of information extracted:

  1. Entity Information:
  • Company Name: Mangoceuticals, Inc.
  • CIK (Central Index Key): 0001938046
  • State of Incorporation: Texas (TX)
  • SEC File Number: 001-41615
  • EIN (Employer Identification Number): 87-3841292
  • Address: 15110 N. Dallas Parkway, Suite 600, Dallas, TX 75248
  • Contact Number: (214) 242-9619
  1. Filing Information:
  • Form Type: 8-K (a report of unscheduled material events or corporate changes)
  • Filing Date: December 18, 2024
  1. Stock Information:
  • Common Stock: Par Value of $0.0001 per share
  • Ticker Symbol: MGRX
  • Exchange: NASDAQ
  1. Reporting Context:
  • Reporting Date: As of December 18, 2024
  • Units of Measure:
    • Currency: USD (United States Dollar)
    • Shares: Represented in units of shares
  1. Miscellaneous:
  • The document adheres to the XBRL (eXtensible Business Reporting Language) format, which indicates it is designed for structured financial data reporting.

Insights:

  • The filing is significant as it is an 8-K, which typically reports major events that shareholders should be aware of, suggesting that there may have been a notable event or decision made by the company around this date.
  • The stock information indicates a low par value, which may reflect the company’s growth stage or capital structure strategy.
  • The company operates in Texas, and its listing on NASDAQ suggests that it is subject to rigorous reporting and regulatory requirements, which can be a positive signal for investors regarding transparency and governance.

Overall, this financial report section provides a snapshot of Mangoceuticals, Inc.'s corporate identity, recent reporting obligations, and stock-related information, which are crucial for stakeholders assessing the company’s current status and potential investment opportunities.